Legislation – The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020
Changes to legislation:
There are currently no known outstanding effects for The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020, Section 4.
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Amendment of regulation 194.
“(4A)
Regulation 18 does not apply in connection with the distribution by way of wholesale dealing of a medicinal product to be used for vaccination or immunisation against coronavirus or influenza virus, where the person distributing the medicinal product—
(a)
was supplied with the medicinal product for the purposes of the administration of it under relevant arrangements;
(b)
is supplying the medicinal product for the purposes of the administration of it by the person to whom it is being supplied (or by a person employed or engaged by them) under relevant arrangements; and
(c)
is authorised by the body making the arrangements to supply the medicinal product as mentioned in sub-paragraph (b) under the relevant arrangements.
(4B)
Regulation 18 does not apply in connection with the distribution by way of wholesale dealing of a medicinal product to be supplied or administered in accordance with a protocol of the type mentioned in regulation 247, where the person distributing the medicinal product—
(a)
was supplied with the medicinal product for the purposes of the supply or administration of it to a patient under relevant arrangements;
(b)
is supplying the medicinal product for the purposes of the supply or administration of it to a patient by the person to whom it is being supplied (or by a person employed or engaged by them) under relevant arrangements; and
(c)
is authorised by the body making the arrangements to supply the medicinal product as mentioned in sub-paragraph (b) under the relevant arrangements.
(4C)
In this regulation, “relevant arrangements” means—
(a)
arrangements for the provision of services as part of—
(i)
in England, the health service as defined by section 275(1) of the National Health Service Act 2006 M2,
(ii)
in Scotland, the health service as defined by section 108(1) of the National Health Service (Scotland) Act 1978 M3,
(iii)
in Wales, the health service as defined by section 206(1) of the National Health Service (Wales) Act 2006 M4, and
(iv)
in Northern Ireland, the system of health and social care promoted under section 2(1) of the Health and Social Care (Reform) Act (Northern Ireland) 2009 M5; or
(b)
arrangements for the provision of services (otherwise than as mentioned in sub-paragraph (a)) as part of the medical services of Her Majesty’s Forces.
(4D)
Paragraphs (4A) to (4C) cease to have effect on 1st April 2022.”.